Advertisement

Topics

Cellerant Therapeutics, Inc. Awarded $6.86 Million Grant From California Institute for Regenerative Medicine to Support Development of Novel Antibody-Drug Conjugate for AML

09:00 EDT 22 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Cellerant Therapeutics, Inc., a clinical-stage company developing innovative immunotherapies for hematologic malignancies and other blood-related disorders, today announced it has been awarded a grant from the California Institu...

Other Sources for this Article

Cellerant Therapeutics, Inc.
Rodney Young, 650-232-2122
Chief Financial Officer
info@cellerant.com

NEXT ARTICLE

More From BioPortfolio on "Cellerant Therapeutics, Inc. Awarded $6.86 Million Grant From California Institute for Regenerative Medicine to Support Development of Novel Antibody-Drug Conjugate for AML"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...